OncoMatch/Clinical Trials/NCT06795009
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Is NCT06795009 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Zanzalintinib and Paclitaxel for uterine cancer.
Treatment: Zanzalintinib · Paclitaxel — The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Allowed: MMR deficient mismatch repair
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Allowed: MSH2 microsatellite instability-high
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Allowed: HER2 (ERBB2) targetable alteration
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy
Patients must have experienced either prior progression on a platinum-based therapy or intolerance to platinum
Must have received: targeted therapy
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Cannot have received: zanzalintinib (zanzalintinib)
Any prior treatment with zanzalintinib
Cannot have received: tyrosine kinase inhibitor
any prior treatment with any tyrosine kinase inhibitor (TKI)
Cannot have received: bevacizumab (bevacizumab)
any prior treatment with bevacizumab
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Cannot have received: cytotoxic chemotherapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: radiation therapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: targeted therapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: immunotherapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: investigational agent
Receipt of any other investigational agents or has received an investigational agent within 4 weeks of start of study treatment
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 K/cumm without G-CSF support within 2 weeks of screening. Platelets ≥ 100 K/cumm without transfusion within 2 weeks. Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks.
Kidney function
Serum creatinine < 1.5 x ULN OR calculated or measured creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault equation)
Liver function
Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease ≤ 3 x ULN). ALT, AST, and ALP ≤ 3 x ULN. For subjects with documented bone metastasis ALP ≤ 5 x ULN.
Cardiac function
INR ≤ 1.5 x IULN, aPTT ≤ 1.2 x IULN, QTcF ≤ 480 ms within 14 days per ECG (average of 3 consecutive results)
Adequate bone marrow and organ function within 14 days prior to first dose of study treatment, as defined below: Absolute neutrophil count ≥ 1.5 K/cumm...QTcF ≤ 480 ms within 14 days per ECG
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
- Washington University School of Medicine · St Louis, Missouri
- University of New Mexico · Albuquerque, New Mexico
- University of Oklahoma · Oklahoma City, Oklahoma
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify